The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GSK | +72.8% | +107.06% | +15.65% | +225% |
| S&P | +13.95% | +78.35% | +12.25% | +422% |
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Commercial Operations, Research and Development, and Consumer Healthcare. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Learn about the companies that are manufacturing vaccines and what you should know before investing in vaccine stocks.
The U.S. has significant pharmaceutical trade deficits with Ireland, Switzerland, and Singapore.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $11.46B | 10.2% |
| Gross Profit | $7.95B | 11.2% |
| Gross Margin | 69.38% | 0.6% |
| Market Cap | $98.92B | 43.4% |
| Market Cap / Employee | $1.44M | 0.0% |
| Employees | 68.6K | 0.0% |
| Net Income | $966.83M | 50.6% |
| EBITDA | $2.34B | -7.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.57B | -5.7% |
| Accounts Receivable | $10.05B | 44.2% |
| Inventory | 8K | 12.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $19.78B | 7.9% |
| Short Term Debt | $4.05B | 37.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 9.61% | 5.3% |
| Return On Invested Capital | 13.26% | -0.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.99B | -5.9% |
| Operating Free Cash Flow | $2.74B | -3.2% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 19.87 | 17.68 | 12.14 | 13.20 | -37.54% |
| Price to Book | 4.62 | 4.29 | 4.31 | 4.54 | 23.67% |
| Price to Sales | 1.99 | 1.93 | 2.10 | 2.32 | 32.95% |
| Price to Tangible Book Value | -7.15 | -6.73 | -8.71 | -9.36 | 39.80% |
| Price to Free Cash Flow TTM | 25.57 | 17.60 | 19.13 | 22.33 | -7.57% |
| Enterprise Value to EBITDA | 26.14 | 25.33 | 24.07 | 50.85 | 49.16% |
| Free Cash Flow Yield | 3.9% | 5.7% | 5.2% | 4.5% | 8.19% |
| Return on Equity | 22.3% | 23.0% | 35.6% | 38.5% | 101.37% |
| Total Debt | $23.79B | $23.78B | $23.90B | $23.83B | 12.04% |
A look at the complicated and emotionally fraught world of pharmaceutical drug marketing.
Digesting how the U.K. decision to exit the EU could affect healthcare stocks here and abroad.
GlaxoSmithKline takes on Pfizer, and Biogen battles Celgene in this healthcare edition of Industry Focus.
GSK earnings call for the period ending September 30, 2021.
GSK earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
